key: cord-0995542-0bxnzy20
authors: Yuan, Weifeng; Hou, Yuechi; Lin, Qiuyan; Chen, Libin; Ren, Tao
title: How China responds to Omicron
date: 2022-04-09
journal: J Infect
DOI: 10.1016/j.jinf.2022.04.017
sha: a3f05bfd150379c825498e434967055378aec742
doc_id: 995542
cord_uid: 0bxnzy20

nan

Recently, a letter in your journal predicted that the SARS-CoV-2 Omicron strain will thereby replace the Delta variant as the dominant strain (1) . This prediction has become ever more salient due to the new wave of COVID-19 outbreaks that has occurred in China. This round of epidemic is mainly caused by the Omicron subtype BA.2. Since the day when the first Omicron cases were confirmed and reported to April 3rd 2022, more than 100-thousand people had been infected. The current epidemic in China is unique in its extremely high infection rate as well as the high frequency of its outbreaks over the entire country, which has caused serious challenges in the prevention and control of the epidemic.

Compared with the original and the Delta strains, the replication ability of the BA.2 strain in the lungs is greatly reduced, rendering the virus' pathogenicity greatly weakened.This has resulted in symptoms that are milder than influenza and close to the level of the common cold(2).

The hospitalization rate and ICU rate of infected persons have decreased, and the median period of hospitalization has also decreased(3). Nevertheless, the BA.2 strain has become extremely infectious-the R0 may be as high as 9. Even with the lower pathogenicity and fatality rate, the mortality rate will increase significantly when a large-scale outbreak occurs, with the death concentrated among the elderly, especially those who have comorbidities and yet to be 

Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern

Antibody titers and breakthrough infections with Omicron SARS-CoV-2

SARS-CoV-2 Omicron variant: Characteristics and prevention

Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines

Lessons learned from the fifth wave of COVID-19 in

Hong Kong in early 2022

In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery